Home
About
Overview
Sharing Data
ORCID
Help
History (8)
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.
Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing.
Fat-like cadherins in cell migration-leading from both the front and the back.
Persistent Disparities in Colorectal Cancer Screening: A Tell-Tale Sign for Implementing New Guidelines in Younger Adults.
Immune Checkpoint Inhibitor Therapy in Breast Cancer.
See All 8 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Immune Checkpoint Inhibitor Therapy in Breast Cancer.
Immune Checkpoint Inhibitor Therapy in Breast Cancer. J Natl Compr Canc Netw. 2018 10; 16(10):1259-1268.
View in:
PubMed
subject areas
Antineoplastic Agents, Immunological
Antineoplastic Combined Chemotherapy Protocols
B7-H1 Antigen
Biomarkers, Tumor
Breast
Breast Neoplasms
Chemoradiotherapy, Adjuvant
Clinical Trials as Topic
CTLA-4 Antigen
Female
Humans
Mastectomy
Molecular Targeted Therapy
Neoadjuvant Therapy
Precision Medicine
Programmed Cell Death 1 Receptor
Receptor, ErbB-2
Receptors, Estrogen
Receptors, Progesterone
Treatment Outcome
authors with profiles
Rita Nanda